ABSTRACT

Positron emission tomography/magnetic resonance imaging (PET/MRI) is the next-generation hybrid imaging, combining the strengths of MRI and PET in a single examination, potentially reducing the need for multiple imaging sessions and radiation exposure in patients. By combining the morphological data provided by MRI with high soft tissue contrast and metabolic information from PET, it can be used as an accurate and effective diagnostic tool for delineating primary tumor margins, nodal staging, evaluating distant and local recurrences and treatment response in patients with gynecologic cancer. Beyond staging, functional and metabolic parameters derived from PET/MRI have the potential to be non-invasive biomarkers of prognosis.